May 3rd 2023
The novel vaccine, from biopharma company GSK, is approved to prevent RSV-associated lower respiratory tract disease in adults aged ≥60 years.
Community Practice Connections™: State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
View More
Evolving Paradigms in Transplant-Related CMV Prevention and Management: Setting Foundations for Improved Patient Outcomes
View More
Community Practice Connections™: Evolving Paradigms in Transplant-Related CMV Prevention and Management: Setting Foundations for Improved Patient Outcomes
View More
6th Annual Advanced Practice Collaborative
09/08/2023-09/09/2023
View More